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Teicoplanin use and emergence of
Staphylococcus haemolyticus: is there a
link?
We read with great interest the meta-analysis of
Vardakas et al. [1] which evaluated the effective-
ness and safety of perioperative prophylaxis with
teicoplanin, compared with ﬁrst- or second-gen-
eration cephalosporins, in patients undergoing
orthopaedic and vascular surgery. The authors
concluded that both regimens are equally effect-
ive in terms of the development of infections,
adverse effects and mortality, but suggested that
large-scale use of teicoplanin cannot be recom-
mended because of the likely emergence of
resistance. This phenomenon seems to be partic-
ularly important with Staphylococcus haemolyticus,
an emerging cause of nosocomial infection, which
is now the third most common organism among
clinical isolates of methicillin-resistant staphylo-
cocci [2].
In our hospital, teicoplanin is not used for
perioperative anti-infective prophylaxis, but is
much used for therapy. Indeed, since the early
1990s, 16 000–18 000 200-mg vials have been
administered annually to our patients, compared
with only 6000–8000 500-mg vials of vancomycin
[3]. Under these circumstances, S. haemolyticus,
usually exhibiting methicillin resistance, has been
isolated increasingly from hospitalised patients,
particularly those at highest risk of infection.
During the period 2000–2003, one of the hospital
microbiology laboratories, which received mainly
clinical specimens from post-trauma ⁄post-
surgery and post-transplantation intensive care
units, found that S. haemolyticus was the second
most common cause of coagulase-negative
staphylococcal (CNS) bacteraemia (after Staphy-
lococcus epidermidis), accounting for 22–24% of
CNS isolates annually. The annual rate of tei-
coplanin resistance among these S. haemolyticus
blood isolates was 11–29%. Studying patients
with haematological malignancies during the
period June 2000–January 2001 [4], we identiﬁed
22 (8.7%) methicillin-resistant S. haemolyticus
(MRSH) among 252 bacterial and fungal blood
isolates. MRSH was again the second most
common CNS isolate from blood cultures,
accounting for 17.8% of 123 CNS isolates
(methicillin-susceptible CNS were not identiﬁed
to the species level).
It should be stressed that S. haemolyticus
resistance rates to glycopeptides may be under-
estimated, because most isolates, which are
apparently susceptible to these drugs according
to the usual susceptibility tests, may display
growth of isolated colonies at very high vanco-
mycin or teicoplanin concentrations [5]. Thus
ten of 20 S. haemolyticus bacteraemia isolates
from patients in various high-risk areas of our
hospital were fully-resistant to teicoplanin. Most
of these teicoplanin-resistant isolates were rela-
ted genetically and clonally distributed. More-
over, seven of the remaining ten isolates, which
were apparently susceptible, were shown to be
heteroresistant to teicoplanin following further
analysis.
The clinical signiﬁcance of S. haemolyticus is not
yet deﬁned fully. Our data show that isolation of
MRSH from bacteraemic patients with haemato-
logical malignancies is associated with negligible
morbidity ⁄mortality rates; however, MRSH
isolates with decreased susceptibility (MIC
16 mg ⁄L) or resistance (MIC ‡32 mg ⁄L) to tei-
coplanin show a lower clinical response rate to
this glycopeptide than do isolates that are fully
susceptible [4]. More importantly, preliminary
data from an ongoing retrospective clinical and
microbiological analysis, currently including 15
well-documented MRSH infections, show that
MRSH may be a cause of severe disease, inclu-
ding infective endocarditis (infections of three
prosthetic valves and one native valve infection),
post-neurosurgery meningitis (ﬁve cases, of
which four were shunt-associated infections),
prosthetic joint infection (two cases), and other
foreign body-associated infections (four cases).
Most of these infections were caused by isolates
that were resistant to teicoplanin, and poor
susceptibility in vitro was associated with clinical
failure of teicoplanin therapy.
In conclusion, it seems that prophylaxis with
teicoplanin may be considered in hospital settings
where the development of infections with multi-
resistant staphylococci is likely, provided that
rigorous surveillance and monitoring of the poss-
ible nosocomial spread of teicoplanin-resistant
S. haemolyticus is also performed.
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Turkish isolates of Helicobacter pylori
belong to the Middle Eastern genotypes
We were interested to read the recent accounts in
CMI regarding the distribution of Helicobacter
pylori genotypes in Mexico and Argentina [1,2].
Epidemiological studies suggest that the preval-
ence of H. pylori infection varies between devel-
oped and developing countries, as well as
according to ethnicity, place of birth and socio-
economic factors, even among people living in the
same country. Molecular epidemiological studies
are important in order to elucidate the circulating
genotypes.
In order to investigate the reason(s) for the high
prevalence of H. pylori infection and gastric can-
cer in Turkey, the cagA, vacA and iceA genes were
used as molecular markers to characterise isolates
from patients infected with H. pylori. In total, 87
isolates of H. pylori from adult patients were
investigated. Antral gastric biopsy samples taken
from patients were cultured using standard
methods [3]. The presence of the cagA gene, the
mid-region of the vacA gene, the signal sequences
of the vacA gene, and the iceA genotype were
determined by PCR as described previously [4–6].
For vacA, the most common genotype was vacA
m2s2, followed by vacA m2s1a. In total, 40 (46%)
isolates were cagA-positive, and 62 (71.3%) iso-
lates were iceA positive. Of these, 28 were positive
for iceA1 only, 12 for iceA2 only, and 22 for both
iceA1 and iceA2.
The fact that 37% and 33% of the isolates,
respectively, belonged to the s1 and s2 geno-
types, and that 46% of the isolates were cagA-
positive, suggests a strong similarity to the
Middle Eastern genotypes [7]. Moreover, the
iceA1 subtype was twice as common as
the iceA2 subtype in the present study, and a
signiﬁcant number of isolates possessed both
iceA1 and iceA2, which also indicates that
Turkish isolates of H. pylori are similar to the
Middle Eastern types.
Only a few samples were found which con-
tained multiple genotypes, which implies that
most infections in Turkey are caused by single
genotypes of H. pylori. Twelve isolates were vacA
s1 cagA+ iceA1 (11 patients with functional dys-
pepsia and one with duodenal ulcer), which are
considered to be the most pathogenic strains.
Only ﬁve isolates were vacAs2m2 iceA (cagA-
negative), which are considered to be the least
pathogenic strains [8].
The present study failed to determine the
genotypes of several isolates, indicating that
mutation had occurred at the primer-binding
sites of the genes investigated. H. pylori is one of
the most genetically diverse bacterial species, and
this mutational diversity has been enhanced by
extensive inter-strain gene transfer and recombi-
nation [9]. Therefore, it is probable that evolution
has selected the H. pylori strains that are best able
to colonise the population of Turkey. Future
studies should focus on determining the genetic
sequences of these strains.
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